Overview
SE JCI (Glendale), DST (marketed as the Johnson Controls R&D DST) is a single-tenant net-lease Delaware Statutory Trust sponsored by Syndicated Equities. The Trust owns a newly constructed 2024 build-to-suit, single-story R&D and engineering laboratory/innovation center at 2022 W. Florist Avenue in Glendale (Milwaukee MSA), Wisconsin, approximately 109,500 SF on a site with 242 parking spaces, delivered in warm-shell condition with the tenant completing a specialized interior lab build-out (a $11.7M tenant improvement allowance funded by the seller), situated directly across from Johnson Controls North American Headquarters campus. The Property is 100% net leased to Johnson Controls, Inc. (the operating subsidiary of NYSE-listed Johnson Controls International PLC) on a 15-year triple-net lease commencing October 2024 and expiring September 2039, at an initial base rent of $2,861,702 ($26.14/SF) escalating annually to $34.49/SF by year 15, with three 5-year renewal options at 95% of market; the tenant bears taxes, insurance, utilities, and maintenance. Total capitalization is $49,488,000: $22,230,000 of equity plus a $27,258,000 non-recourse Old National Bank loan (60% loan-to-purchase-price, ~55% loan-to-cost; ~6.10% fixed; interest-only for 36 months then 30-year amortization; 10-year term), against a $45,430,000 purchase price. The thesis is a leveraged, income-oriented net-lease hold of an investment-grade-affiliated tenant in a strategic headquarters-adjacent location, with disposition targeted around the 10-year loan term.
Highlights
The Property is fully leased to Johnson Controls, Inc., the operating subsidiary of investment-grade Johnson Controls International PLC (NYSE: JCI; rated BBB+ by S&P; ~$23.6B in 2025 net sales, 94,000-plus employees). The critical nuance is that the parent does not guaranty the lease, so the contractual obligor is the unrated subsidiary rather than the rated parent; the headline investment-grade profile provides reputational and operational comfort but not a direct credit backstop, a distinction that materially affects the durability of the income stream.
The asset sits directly across from Johnson Controls North American Headquarters in Glendale, a strategic adjacency that supports the tenant long-term operational commitment and integrates the lab into JCI R&D footprint in a metro where the company traces its roots to 1885. The counterweight is that this same adjacency ties the asset fate to JCI continued Milwaukee-area presence, and the company post-Tyco reincorporation in Ireland is a reminder that corporate footprint decisions can shift over a 15-year horizon.
The newly built 2024 build-to-suit carries a 15-year triple-net lease with annual escalations (from $26.14/SF to $34.49/SF by year 15) and full expense pass-through, providing long-dated, low-management contractual cash flow, with in-place rent modestly below Class A market asking (~$27.70/SF) implying limited over-rent risk. The offset is that the specialized laboratory build-out is highly tenant-specific, so alternative-use flexibility is limited and re-leasing cost and downtime would be significant if Johnson Controls does not renew at the 2039 expiry, and its renewal options are struck at 95% of market, a slight tenant discount.
Leverage is moderate at 60% loan-to-purchase-price (~55% loan-to-cost) on a 10-year non-recourse loan at a projected 6.10% fixed rate, interest-only for the first 36 months. The structure front-loads distributable cash (Year-1 cash-on-cash ~6.03%) but steps down when amortization begins (to ~4.99% in Year 4), and because the 10-year loan matures roughly five years before the 2039 lease expiry, the hold carries refinancing or forced-sale pressure around 2036, with the rate not yet locked at the Memorandum date.
Syndicated Equities is an established Chicago-based sponsor active since 1986, with over $2 billion of institutional-quality acquisitions across office, medical office, retail, and industrial product and a senior team with 100-plus combined years of experience, providing institutional underwriting and asset management. The consideration is a relatively high fee load (acquisition, due-diligence, and loan-placement/guaranty fees aggregating ~16% of equity) and customary affiliated-party conflicts, with broker-dealer commissions funded by the Sponsor out of its fees rather than charged separately.
Analysis
Insights
This is a conventional leveraged single-tenant net-lease acquisition whose appeal rests on long-dated contractual income from a facility integrated into Johnson Controls headquarters ecosystem, but whose risk-adjusted profile is more nuanced than the investment-grade headline suggests. The central credit question is the gap between the rated, non-guarantying parent and the unrated subsidiary that actually signs the lease; the asset value is underwritten to JCI continued occupancy of a purpose-built lab it helped design, so the practical risk is operational commitment rather than balance-sheet default. The financing is the second analytical pivot: moderate leverage at a thin positive-leverage spread, with a 36-month interest-only runway masking the amortization step-down that arrives in Year 4, and a 10-year loan maturing well inside the 15-year lease that imports refinancing risk into a 2036 rate environment that cannot be known today. The roughly 5.90% average cash-on-cash and modestly below-market in-place rent are reasonable for a newly built, HQ-adjacent net-lease asset, but the high fee load, single-tenant and single-asset concentration, specialized improvements, and loan-versus-lease maturity mismatch are the idiosyncratic items least reflected in the headline distribution rate, and they argue for evaluating the offering on a hold-to-refinance, credit-of-the-actual-obligor basis.
Advantages
The offering provides long-dated, low-touch contractual income: a newly built 2024 build-to-suit R&D laboratory on a 15-year triple-net lease to Johnson Controls, Inc., the operating subsidiary of an investment-grade global parent, with strong annual rent escalations and full expense pass-through, located strategically across from Johnson Controls North American Headquarters in the Milwaukee market. In-place rent (~$26.14/SF) sits modestly below Class A market asking, limiting over-rent risk, and the asset is financed with moderate, non-recourse leverage (60% loan-to-purchase-price) at a projected 6.10% fixed rate with a 36-month interest-only period that supports a ~6.03% initial cash-on-cash building to ~6.75% by year ten (5.90% average). Syndicated Equities is an experienced sponsor (active since 1986; $2B-plus of acquisitions), and broker-dealer commissions are borne by the Sponsor rather than charged directly to the offering.
Concerns
All income depends on a single tenant in a single special-purpose asset, and critically the lease obligor is Johnson Controls, Inc., the unrated operating subsidiary, while the investment-grade rating belongs to the non-guarantying parent, so the headline credit overstates the direct backstop. The laboratory build-out is highly tenant-specific with limited alternative use, creating substantial re-leasing cost and downtime risk if the tenant does not renew at the 2039 expiry (and renewals are struck at 95% of market), while the 10-year loan matures around 2036, roughly five years before lease expiry, concentrating refinancing or forced-sale risk, with the fixed rate still unlocked at the Memorandum date (the Sponsor contributes additional equity, reducing its promote, only if the rate exceeds 5.90%). Positive leverage is thin, and once the 36-month interest-only period ends, amortization compresses distributions to roughly 4.99% in Year 4 before rent escalations rebuild them. The fee load is high relative to peers (acquisition ~2.75% of price, due diligence ~3.0% of price, and a loan-placement/guaranty fee ~2.65% of the loan, aggregating ~16% of equity), the Sponsor retains any savings between estimated and actual third-party costs, and the asset fortunes are tied to Johnson Controls continued Milwaukee-area presence following the parent earlier reincorporation abroad.
